ArticleBMC veterinary research2026
Molecular characterization of rabbit hemorrhagic disease virus type 2 and long-lasting protection conferred by a VLP-based vaccine.
Article in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRabbit hemorrhagic disease virus (RHDV) type 2 (GI.2) is an emerging pathogen genetically distinct from classic RHDV (GI.1). It can infect young, wild, and even vaccinated rabbits, and may also contract RHD. This study investigated the prevalence of RHD in China. Furthermore, a virus-like particle (VLP) vaccine was developed based on the prevalent strains, and the vaccine’s protective efficacy against different strains as well as the duration of antibody persistence were evaluated.
resultsFrom 2020 to 2024, 205 clinical samples were collected from 16 cities in China. Among them, 86 samples tested positive for RHDV-2, while no classical RHDV-1 was detected. Furthermore, the VP60 gene of RHDV-2 was sequenced from 18 positive samples. These sequences showed greater than 95% nucleotide identity with the reference strain of RHDV-2 (GenBank accession number: MT383749). However, recombination analysis indicated a potential risk of recombination between RHDV-2 and RHDV-1. A recombinant baculovirus expressing the VP60 gene from the RHDV2 YC05 strain was constructed, and molecular characterization confirmed that the VP60 capsid protein was efficiently expressed in baculovirus-infected Sf9 cells. Hemagglutination activity reached a titer of 1:214 at 4 days post-infection, and the expressed protein self-assembled into virus-like particles (VLPs) in the infected Sf9 cells. Immunization with VLPs containing RHDV2-VP60 at an HA titer of 1:28 induced specific antibodies against RHDV2-VP60 in rabbits, with hemagglutination inhibition titers ensured at 1:25 or higher. All rabbits immunized with the VLP vaccine survived challenge with different clinical RHDV2 strains and remained fully protected for at least 180 days.
conclusionsOur results demonstrated that RHDV2 has become widely prevalent and is now the dominant pathogen in China. Recombinant RHDV-2 VP60 protein expressed in the baculovirus-insect system demonstrates robust immunogenicity and confers long-term protection, making them a promising vaccine candidate for preventing RHDV2 infection in rabbits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.